Skip to main content
2024 AAPD Annual Meeting Main banner
Itinerary Planner Sponsored by Cheng Crowns
Information & Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticket Required
Ticket Required
Sold Out
Sold Out
Recorded Session
Recorded Session
Back
Rate ePoster
View ePoster

Pulp Therapy

334 - Antibacterial Assessment of Children’s Afrin® Against Rothia dentocariosa

Friday, May 24, 2024
3:45 PM – 3:55 PM EST
Location: Exhibit Hall (back left corner of the hall, space 137)

    Presenting Author(s)

  • Roman M. Garcia, DMD, MPH

    Pediatric Dental Resident
    University of Minnesota, Minneapolis, MN
    University of Minnesota
    Minneapolis, Minnesota, United States

    • Co-Author(s)

  • RJ

    Robert Jones, DDS, PhD

    University of Minnesota

    • Research Mentor(s)

  • DK

    Dhiraj Kumar, PhD

    University of Minnesota
    Minneapolis, Minnesota, United States

    • Program Director(s)

  • Jeffrey Karp, D.M.D., M.S.

    Residency Program Director
    University of Minnesota, Minneapolis, MN
    School of Dentistry , University of Minnesota
    Minneapolis, Minnesota, United States

Abstract:



Purpose: To evaluate and compare the antibacterial and hemostatic properties of Children’s Afrin®, Afrin Original®, Oxymetazoline, and Benzalkonium Chloride against Rothia dentocariosa.  

 



Methods: Rothia bacterial cells were grown overnight in brain-heart infusion (BHI) broth media. The bacterial cells were diluted to 0.6 OD at 600 nm, followed by cell suspension spread over agar plates. Whatman discs (6mm) were dried with each reagent, Oxymetazoline (Oxym, 0.05%; 0.025%), Benzalkonium Chloride (BKC, 0.025%; 0.0125%), Afrin Original® (Oxym 0.05% with BKC), and Children’s Afrin® (Oxym 0.025% with BKC) and exposed to the bacterial cell bed to study the antibacterial property using a disc inhibition assay. An antibacterial broth inhibition test was performed. The optical density at 600nm and pH for each sample type were recorded at defined time intervals (0, 1, 2, 4, and 8 hrs). 

 



Results: Disc inhibition assay showed Afrin Original®, Children’s Afrin®, and Benzalkonium Chloride (0.025%) had the largest zone of inhibition compared to control, BKC (0.0125%), and Oxym (0.025% and 0.05%). The observed discs inhibition assay reported a statistically significant larger zone of inhibition, confirming the stronger antibacterial properties. A decreased OD of broth exposed to Benzalkonium Chloride (0.025%; 0.0125%), Afrin Original® (Oxy-0.05% with BKC), and Children’s Afrin® (Oxy-0.025% with BKC) for up to 8 hours compared to the control and Oxymetazoline (0.05%; 0.025%). 

 



Conclusion: Children’s Afrin® shares the same antibacterial and hemostatic properties of Afrin Original®. The study highlighted the potential application of Children’s Afrin® as an effective pulpal management agent for primary teeth care in kids.

Identify Supporting Agency and Grant Number: Acknowledgements: This work was supported by NIH grant R01DE027669